Cipla surges on getting tentative nod from US FDA for its HIV treatment tablets

18 Oct 2012 Evaluate

Cipla is currently trading at Rs. 363.30, up by 1.35 points or 0.37% from its previous closing of Rs. 361.95 on the BSE.

The scrip opened at Rs. 364.00 and has touched a high and low of Rs. 366.00 and Rs. 361.35 respectively. So far 84,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 395.45 on 10-Sep-2012 and a 52 week low of Rs. 284.00 on 11-Nov-2011.

Last one week high and low of the scrip stood at Rs. 370.50 and Rs. 358.80 respectively. The current market cap of the company is Rs. 29,170 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.23% and 28.73% respectively.

Cipla has received a tentative approval from United States Food and Drug Administration (US FDA) for its HIV treatment tablets, which have a combination of lamivudine, nevirapine and zidovudine drugs.

The company sells the combination drug under the brand name ‘Duovir N’ outside the United States.

Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×